Related Experiment Video
Updated: Aug 15, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Expression and functional influence of cellular retinoic acid-binding protein II in renal cell carcinoma
Ulrike Goelden1, Susanne Pfoertner, Wiebke Hansen
1Department of Cell Biology and Immunology, German Research Centre for Biotechnology, Braunschweig, Germany.
Introduction:
Retinoic acid (RA) and its derivates possess antiproliferative and tumor-suppressive abilities and are successfully used in the treatment of various malignancies. However, in metastatic renal cell carcinoma (RCC), its application did not meet first expectations. As the exact mechanisms of RA action and especially the role of the cellular retinoic acid-binding proteins (CRABP) still remain unclear, we studied the expression of CRABP-II and its potential influence on RA response in RCC.
Materials And Methods:
We used the real-time RT-PCR methodology to investigate CRABP-II expression in 12 RCC samples and corresponding normal kidney tissue. Moreover, CRABP-II was cloned and overexpressed in CAKI-2 RCC cells. CRABP-II (un)transfected CAKI-2 cells were stimulated with all-trans RA (ATRA) and 9-cis RA, and their antiproliferative effects were evaluated using 3H-thymidine-proliferation assays.
Results:
Using RPS9 and RPLP0 to normalize its expression, the median tumor/kidney ratio for CRABP-II expression was 0.16 and 0.12, respectively. Using proliferation assays, CRABP-II overexpressing CAKI-2 cells did not exhibit a significant change in RA sensitivity, but appeared to be less sensitive toward RA-stimulation compared to CAKI-2 cells expressing naturally low levels of CRABP-II (maximum difference, 59% at 3 microM ATRA).
Conclusions:
We were able to demonstrate a downregulation of CRABP-II expression in primary RCC tumor samples compared to the corresponding normal kidney tissue. However, CRABP-II overexpression in CAKI-2 RCC cells did not significantly influence RA associated antiproliferative actions. Further experiments are necessary to define the exact role of CRABP-II and its downregulation in RCC including its influence and dependence on other molecules involved in RA signalling and metabolism.
Insights
Retinoic acid (RA) shows promise in cancer treatment, but its effectiveness in renal cell carcinoma (RCC) is limited. This study found CRABP-II is downregulated in RCC tumors, and its overexpression did not significantly alter RA
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Retinoic acid (RA) derivatives have demonstrated antiproliferative and tumor-suppressive properties, utilized in treating various cancers.
- The efficacy of RA in metastatic renal cell carcinoma (RCC) has not met initial expectations, necessitating further investigation into its mechanisms.
- The precise roles of RA action and cellular retinoic acid-binding proteins (CRABP) in RCC remain unclear.
Purpose of the Study:
- To investigate the expression of cellular retinoic acid-binding protein II (CRABP-II) in renal cell carcinoma (RCC).
- To evaluate the potential influence of CRABP-II on the response to retinoic acid (RA) in RCC.
- To explore the relationship between CRABP-II expression levels and RA-induced antiproliferative effects in RCC cells.
Main Methods:
- Real-time RT-PCR was employed to assess CRABP-II expression in 12 RCC samples and adjacent normal kidney tissues.
- CRABP-II was cloned and overexpressed in the CAKI-2 RCC cell line.
- Antiproliferative effects of all-trans RA (ATRA) and 9-cis RA were evaluated in CRABP-II (un)transfected CAKI-2 cells using 3H-thymidine-proliferation assays.
Main Results:
- CRABP-II expression was found to be downregulated in primary RCC tumor samples compared to corresponding normal kidney tissue (median tumor/kidney ratios of 0.16 and 0.12).
- Overexpression of CRABP-II in CAKI-2 RCC cells did not lead to a significant change in sensitivity to RA.
- CRABP-II overexpressing cells appeared less sensitive to RA stimulation than cells with naturally low CRABP-II levels.
Conclusions:
- CRABP-II expression is downregulated in primary RCC tumors relative to normal kidney tissue.
- Overexpression of CRABP-II in RCC cells did not significantly impact RA-mediated antiproliferative effects.
- Further research is required to elucidate the exact function of CRABP-II and its downregulation in RCC, including its interactions within the RA signaling pathway.
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Negative Regulator Molecules
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Cell Specific Gene Expression
Regulation of Angiogenesis and Blood Supply
